- Home
- PLCE vs STXS Comparison
PLCE vs STXS Comparison
Compare PLCE & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLCE
- STXS
- Stock Information
- Founded
- PLCE 1969
- STXS 1990
- Country
- PLCE United States
- STXS United States
- Employees
- PLCE N/A
- STXS N/A
- Industry
- PLCE Clothing/Shoe/Accessory Stores
- STXS Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- PLCE Consumer Discretionary
- STXS Health Care
- Exchange
- PLCE Nasdaq
- STXS Nasdaq
- Market Cap
- PLCE 174.5M
- STXS 173.5M
- IPO Year
- PLCE 1997
- STXS 2004
- Fundamental
- Price
- PLCE $14.04
- STXS $2.03
- Analyst Decision
- PLCE Hold
- STXS Strong Buy
- Analyst Count
- PLCE 3
- STXS 2
- Target Price
- PLCE $11.33
- STXS $4.50
- AVG Volume (30 Days)
- PLCE 338.9K
- STXS 295.7K
- Earning Date
- PLCE 11-26-2024
- STXS 11-11-2024
- Dividend Yield
- PLCE N/A
- STXS N/A
- EPS Growth
- PLCE N/A
- STXS N/A
- EPS
- PLCE N/A
- STXS N/A
- Revenue
- PLCE $1,522,802,000.00
- STXS $25,143,000.00
- Revenue This Year
- PLCE N/A
- STXS $1.16
- Revenue Next Year
- PLCE N/A
- STXS $55.65
- P/E Ratio
- PLCE N/A
- STXS N/A
- Revenue Growth
- PLCE N/A
- STXS N/A
- 52 Week Low
- PLCE $4.77
- STXS $1.41
- 52 Week High
- PLCE $38.03
- STXS $3.29
- Technical
- Relative Strength Index (RSI)
- PLCE 52.79
- STXS 52.54
- Support Level
- PLCE $12.93
- STXS $1.88
- Resistance Level
- PLCE $16.07
- STXS $2.27
- Average True Range (ATR)
- PLCE 1.15
- STXS 0.12
- MACD
- PLCE 0.02
- STXS 0.02
- Stochastic Oscillator
- PLCE 46.30
- STXS 46.67
About PLCE Children's Place Inc. (The)
Children's Place Inc operate an omni-channel children's specialty portfolio of brands in North America. It design, contract to manufacture, and sell fashionable, high-quality apparel, accessories and footwear predominantly at value prices under proprietary The Children's Place, Place, Baby Place, Gymboree, Sugar & Jade, and PJ Place brand names.
About STXS Stereotaxis Inc.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service and accessories stream. The company generates the majority of revenue from the United States.